Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J.L. Reagan
Rituximab Alone (R) Versus Rituximab Plus Bendamustine (Br) for Splenic (Smzl) and Nodal Marginal Zone Lymphoma (Nmzl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma
British Journal of Haematology
Hematology
Post Hoc Analyses of Patients With Relapsed/Refractory Marginal Zone Lymphoma Who Received Lenalidomide Plus Rituximab (R2 ) vs Rituximab/Placebo (Augment)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Splenic Marginal Zone Lymphoma
Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab-Bendamustine (R-Benda) in MALT Lymphoma Complicating Primary Sjögren Syndrome (pSS)
British Journal of Haematology
Hematology
Multi-Omics Landscape of Splenic Marginal Zone Lymphoma (Smzl) - Interim Analysis of Ielsg46 Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Maintenance Rituximab Is Associated With Improved Overall Survival in Mantle Cell Lymphoma Patients Responding to Induction Therapy With Bendamustine + Rituximab (Br)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma
American Journal of Hematology
Hematology
